139 Invossa patients win first lawsuit as manufacturing defect is acknowledged
In the Invossa damages lawsuit, a manufacturing defect was acknowledged with the first victory for 139 patients. A ruling for compensation of up to 45 million won is drawing attention to the future direction of similar lawsuits.
139 patients who were administered Invossa have won for the first time in a damages lawsuit against the manufacturer. The court determined that the drug had a manufacturing defect.
The ruling was issued on July 10, 2026, and some patients were reportedly awarded damages of up to 45 million won per person.
This decision is the first case in a dispute related to Invossa in which the patients' claims were legally accepted, and it could also affect similar lawsuits in the future.